Brief: Newron And Zambon Sign Agreement For Study On Safinamide In Parkinson's Disease Patients
15/03/2021 06:03
March 15 (Reuters) - NEWRON PHARMACEUTICALS SPA NWRN.S :
* NEWRON AND ZAMBON SIGN AGREEMENT FOR POTENTIALLY PIVOTAL
STUDY
WITH SAFINAMIDE IN PARKINSON'S DISEASE PATIENTS
* UNDER AGREEMENT, NEWRON WILL SPONSOR STUDY AND BE
RESPONSIBLE
FOR ITS DEVELOPMENT AND EXECUTION, AS WELL AS LEADING ON ALL
RELATED REGULATORY INTERACTIONS
Source text for Eikon: ID:nEQ46s984a
Further company coverage: NWRN.S
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Newron Pharmaceuticals SpA
See all newsUS FDA flags four deaths in Newron's schizophrenia drug studies (updated)
US FDA cites 4 deaths in Newron's schizophrenia drug trial hold
Brief: Newron Says Topline Data From ENIGMA-TRS 1 Expected In Q1 2027
Brief: Newron Provides Update Following Type A Meeting With The FDA
Brief: Newron Reports Pause Of Enrollment Of New Study Participants In US Centers Of ENIGMA-TRS 2 Study